Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Juncture Wealth Strategies LLC

Juncture Wealth Strategies LLC cut its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,398 shares of the company’s stock after selling 200 shares during the quarter. Juncture Wealth Strategies LLC’s holdings in Neurocrine Biosciences were worth $968,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in NBIX. Sendero Wealth Management LLC raised its holdings in shares of Neurocrine Biosciences by 2.7% in the 3rd quarter. Sendero Wealth Management LLC now owns 20,272 shares of the company’s stock valued at $2,336,000 after purchasing an additional 537 shares in the last quarter. Perpetual Ltd raised its holdings in shares of Neurocrine Biosciences by 96.6% in the 3rd quarter. Perpetual Ltd now owns 12,560 shares of the company’s stock valued at $1,447,000 after purchasing an additional 6,170 shares in the last quarter. CWM LLC raised its holdings in shares of Neurocrine Biosciences by 15.1% in the 3rd quarter. CWM LLC now owns 7,884 shares of the company’s stock valued at $908,000 after purchasing an additional 1,035 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Neurocrine Biosciences by 11.9% in the 3rd quarter. GAMMA Investing LLC now owns 1,738 shares of the company’s stock valued at $200,000 after purchasing an additional 185 shares in the last quarter. Finally, Handelsbanken Fonder AB raised its holdings in shares of Neurocrine Biosciences by 20.7% in the 3rd quarter. Handelsbanken Fonder AB now owns 26,867 shares of the company’s stock valued at $3,096,000 after purchasing an additional 4,600 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Stock Up 2.7 %

Shares of NASDAQ:NBIX opened at $115.49 on Friday. The company has a market cap of $11.62 billion, a price-to-earnings ratio of 31.82 and a beta of 0.36. The firm’s 50-day simple moving average is $129.62 and its 200-day simple moving average is $135.74. Neurocrine Biosciences, Inc. has a fifty-two week low of $103.63 and a fifty-two week high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $1.15 by ($0.52). Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The company had revenue of $590.20 million during the quarter, compared to analyst estimates of $545.98 million. During the same quarter last year, the business earned $0.95 EPS. The firm’s revenue for the quarter was up 30.4% on a year-over-year basis. On average, research analysts forecast that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on NBIX shares. HC Wainwright restated a “buy” rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, August 29th. Royal Bank of Canada cut their price target on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a research note on Friday, October 4th. Robert W. Baird lifted their price target on shares of Neurocrine Biosciences from $157.00 to $180.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Oppenheimer lifted their price target on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Finally, StockNews.com upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Sunday, August 4th. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $164.52.

Insider Activity at Neurocrine Biosciences

In related news, insider Ingrid Delaet sold 273 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $147.70, for a total value of $40,322.10. Following the completion of the sale, the insider now owns 6,607 shares in the company, valued at $975,853.90. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Neurocrine Biosciences news, insider Ingrid Delaet sold 273 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $147.70, for a total transaction of $40,322.10. Following the completion of the transaction, the insider now owns 6,607 shares in the company, valued at approximately $975,853.90. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Julie Cooke sold 900 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $150.04, for a total transaction of $135,036.00. Following the transaction, the insider now owns 18,202 shares of the company’s stock, valued at approximately $2,731,028.08. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 61,798 shares of company stock worth $9,274,196 over the last 90 days. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.